Compare VYGR & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | AMWL |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.3M | 179.6M |
| IPO Year | 2015 | 2020 |
| Metric | VYGR | AMWL |
|---|---|---|
| Price | $3.09 | $13.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $16.50 | $7.40 |
| AVG Volume (30 Days) | ★ 404.5K | 83.8K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | $34.04 | N/A |
| Revenue Next Year | $7.92 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $3.71 |
| 52 Week High | $5.55 | $14.19 |
| Indicator | VYGR | AMWL |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 58.13 |
| Support Level | $2.95 | $4.60 |
| Resistance Level | $3.30 | $13.45 |
| Average True Range (ATR) | 0.14 | 0.70 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 13.19 | 69.49 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.